ARC's library contains publications and articles published in peer reviewed journals on the latest research that ARC has been engaged in.
Click on image to download report.
Guidance for Industry AL Amyloidosis Developing Drugs for Industry
Developing the guidance involved active participation from all stakeholder groups including patients, medical experts, academics and biopharmaceutical industry representatives. This guidance has been submitted to FDA. ARC is requesting that the FDA issue a draft guidance incorporating the information in this externally-developed draft guidance.
The Voice of the Patient
Summary report resulting from the first Externally-led Patient Focused Drug Development meeting, a parallel effort to the FDA's Patient focused Drug Development Initiative.
Rationale, Application, and Clinical Qualification for Use of NT-proBNP as a Surrogate End Point in Pivotal Clinical Trials in Patients with AL Amyloidosis
Submitted to FDA December 2016
Published June 2016
Published October 2015
Click on image to download article.
Rationale, Application and Clinical Qualification for NT-proBNP as a Surrogate End Point in Pivotal Clinical Trials in Patients with AL Amyloidosis
Published: Leukemia July 2016
Author: G Merlini et al.
Light Chain Amyloidosis Patient Experience Survey from the Amyloidosis Research Consortium
Published: Advances in Therapy 2015
Author: I Lousada et al.
Click on image to download poster.
Recommendations From the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, April 1, 2016
International Symposium of Amyloidosis 2016
Patient Experience With Light Chain Amyloidosis: A Survey From the Amyloidosis Research Consortium
Heart Failure Society of America 2015
Patient Experience With Hereditary and Wild-type Amyloidosis: A Survey from the Amyloidosis Research Consortium
European Congress on Hereditary Amyloidosis 2015